Clinical Trial Update: Study of ABT-869 in Subjects With Advanced Renal Cell Carcinoma Who Have Previously Received Treatment With Sunitinib [Phase 2]

View source ↗

Summary

A Phase 2 study of ABT-869 (linifanib) in advanced renal cell carcinoma following prior sunitinib treatment has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ABT-869 (linifanib)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Advanced Renal Cell Carcinoma | Phase 2 | Status: COMPLETED